Navigation Links
Cytochroma announces appointment of Ulrik Spork to Board of Directors
Date:10/30/2008

MARKHAM, ON, Oct. 30 /PRNewswire/ - Cytochroma today announced the appointment of Ulrik Spork to its Board of Directors. Mr. Spork will represent Novo A/S on the Company's Board and replaces Dr. Soren Schifter, who is leaving Novo A/S. The number of Board members remains unchanged at six members.

"We are very pleased to welcome Ulrik Spork to our board and look forward to drawing on his expertise and experiences as we continue building Cytochroma into a leading CKD-focused specialty pharmaceutical company," stated Alan Lewis, Ph.D., Chairman of Cytochroma's Board of Directors. "We would also like to thank Soren Schifter for his advice to Cytochroma over the years, and wish him well in the future."

Ulrik Spork has significant experience in corporate strategy, business development, M&A, product development, and international marketing. As Senior Partner, he led the establishment of venture investment activities by Novo A/S from its inception in 1999. Prior to the formation of Novo A/S, Mr. Spork was Director of Corporate Development at Novo Nordisk A/S, during which he was involved in that company's strategic planning and managed a number of acquisitions. He holds an MSc in Engineering from the Technical University of Copenhagen and a BSc in International Economics.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD). The Company's vitamin D-based therapeutics are designed to safely and effectively treat patients with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in these same patients. For more information, please visit http://www.cytochroma.com.


'/>"/>
SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
2. Cytochroma opens U.S. headquarters in Illinois
3. Cytochroma Appoints R. Richard Wieland II As CFO
4. Cytochroma Closes $45 Million Series C Financing
5. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
6. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... (TOPEC), the leading medical education provider of women’s health, primary care, and ... Accreditation Council for Continuing Medical Education (ACCME). ACCME’s Accreditation with Commendation is ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the ... from around the world, is pleased to announce the launch of a new scholarship ... mathematics (STEM) fields. , This merit-based scholarship is open to all high school seniors, ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017 ... reported the results of a study that validated the ... pathogens that are associated with increased mortality in immune-suppressed ... transplant patients. The objective of the ... capture of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, ... (OTCQB:CELZ) announced today expansion of its translational research ... product through establishment of laboratory facilities in San ... the San Diego BioLabs facility, a biotechnology incubator ... and Sanofi. In November 2016, the ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, ... on emerging technology, announces the availability of a new report, ... Continue Reading ... ... industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, ...
Breaking Biology News(10 mins):